Biomemory Launches DNA Shield, First Commercial Product Built on Its Molecular IT Platform

Biomemory has officially launched DNA Shield, marking the company's first commercial product based on its proprietary molecular information technology platform. The product leverages DNA-based storage to provide a highly durable and secure medium for long-term data archiving. This milestone follows a period of significant organizational development for the company, including the strategic acquisition of assets from the startup Catalog and the appointment of Laurent Guengant as CEO earlier this year. By utilizing the biological stability of DNA, Biomemory aims to address the growing global demand for sustainable and immutable data storage solutions. The launch signals a shift from experimental molecular computing research to practical, market-ready applications, positioning the company as a key player in the emerging field of synthetic biology-based data infrastructure. Further details on the technical specifications and deployment capabilities of DNA Shield are expected to be disclosed as the company scales its commercial operations.